News
Nymox Says Prostate Drug Is Effective
Canadian drug developer Nymox Pharmaceutical Corp. said its experimental enlarged-prostate treatment was more effective than the widely used drug finasteride in a midstage study.
Finasteride is made by Merck & Co. but lost patent protection for the prostate condition called benign prostatic hyperplasia in 2006. There are several generic versions on the market.
During the Phase II clinical trial, a mix of 85 patients received a one-time injection of Nymox's NX-1207 at either a low or high dose, or received finasteride on a daily basis. Results showed that after 90 days, the one-time dose of NX-1207 was more effective than the continued daily doses of finasteride.
Full results from the study will be released at medical meetings later in 2008. Subjects involved in the study will continue to be monitored for additional effectiveness and safety results.
Nymox had previously conducted three studies on the drug candidate and said the new results confirm prior positive results.
Enlarged prostate, which makes urinating difficult and painful, affects about half of men over the age of 50 and 90 percent of men over the age of 80, Nymox said.
Nymox shares rose 31 cents, or 6 percent, to $5.31 in afternoon trading. The stock has traded between $4.25 and $7.50 over the last 52 weeks.